Drugs / XL418
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00460278 | Apr 2007 → ? | cancer | Exelixis | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00460278 ↗ |
| Action | Inhibit | “inhibits a spectrum of targets, including Akt and p70S6K” NCT00460278 ↗ |
| Modality | Small molecule | — CHEMBL2016893 ↗ |
| Route | Oral | “XL418 Administered Orally Daily” NCT00460278 ↗ |